<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ketogenic dietary therapies for the treatment of epilepsy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ketogenic dietary therapies for the treatment of epilepsy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ketogenic dietary therapies for the treatment of epilepsy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric HW Kossoff, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H21467804"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Published reports of the ketogenic diet as an effective treatment for epilepsy date to the early 1920s [<a href="#rid1">1</a>]. This topic will review the ketogenic dietary therapies (KDTs) for the treatment of epilepsy. These include the classic ketogenic diet, the modified Atkins diet, the low glycemic index treatment, and the medium-chain triglyceride diet.</p><p>Other treatments for refractory seizures and epilepsy are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a> and  <a class="medical medical_review" href="/z/d/html/2229.html" rel="external">"Vagus nerve stimulation therapy for the treatment of epilepsy"</a> and  <a class="medical medical_review" href="/z/d/html/2212.html" rel="external">"Initial treatment of epilepsy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">"Surgical treatment of epilepsy in adults"</a>.)</p><p class="headingAnchor" id="H21468627"><span class="h1">MECHANISMS OF ACTION</span><span class="headingEndMark"> — </span>The classic ketogenic diet is a high-fat, adequate-protein (1 gram/kg), low-carbohydrate diet that produces metabolic changes associated with the starvation state. Changes in plasma ketones, insulin, glucose, glucagon, and free fatty acids can occur within hours of starting the diet and can be quite profound [<a href="#rid2">2</a>]. Which of these metabolic changes are primarily responsible for the improvement in seizure frequency is not known, but the mechanism is likely multifactorial [<a href="#rid2">2</a>].</p><p>The ketogenic diet was so-called based upon the theory that ketone bodies (acetoacetate, acetone, and beta-hydroxybutyrate), created in the liver from long- and medium-chain fatty acids, are directly anticonvulsant when crossing the blood-brain barrier. However, the importance of ketosis in the mechanism of action of KDT is increasingly questioned. KDT is associated with increased mitochondrial biogenesis, oxidative phosphorylation, enhanced gamma-aminobutyric acid (GABA) levels, reduced neuronal excitability and firing, and stabilized synaptic function [<a href="#rid2">2,3</a>]. While these may be induced by ketosis, alternative mechanisms proposed include elevated plasma free fatty acids (including polyunsaturated fatty acids), reduced glucose fluctuations, increased activation of adenosine triphosphate (ATP)-sensitive potassium channels, caloric restriction, and elevated brain amino acids. Inhibition of the mammalian target of rapamycin pathway and decreased glutamatergic synaptic transmission have also been implicated [<a href="#rid4">4</a>].</p><p>In mice, the ketogenic diet induced significant changes in the gut microbiome that led to altered metabolite levels; there were reductions in systemic gamma-glutamylated amino acids and an increase in the ratio of hippocampal GABA to glutamate that correlated with seizure protection in mice [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2170516997"><span class="h1">INDICATIONS</span></p><p class="headingAnchor" id="H1789624404"><span class="h2">Drug-resistant epilepsy</span><span class="headingEndMark"> — </span>For patients with drug-resistant epilepsy, options include KDT as an adjunct or alternative to drug therapy. Antiseizure medications are the primary treatment for epilepsy and are effective in controlling seizures in most patients. However, approximately one-third of patients will not become seizure-free with medications and require nonpharmacologic treatments [<a href="#rid6">6</a>]. Although epilepsy surgery can be a treatment option for these patients, there are many families, guardians, and patients who are unwilling to consider surgery. Others may not be candidates for epilepsy surgery because the region that is causing the seizures overlaps with eloquent cortex and therefore cannot be resected without causing neurologic deficits. In these patients, vagus nerve stimulation (VNS), responsive neurostimulation (RNS), deep brain stimulation (DBS), and KDTs are rational options  (<a class="graphic graphic_algorithm graphicRef139450" href="/z/d/graphic/139450.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures"</a> and  <a class="medical medical_review" href="/z/d/html/2214.html" rel="external">"Evaluation and management of drug-resistant epilepsy"</a>.)</p><p>Based upon the available evidence, a 2018 expert consensus panel recommended that KDT should be offered to children with drug-resistant epilepsy after unsuccessful treatment trials of two antiseizure medications [<a href="#rid7">7</a>]. Some families or caregivers may wish to try it sooner, and in many of those situations it may be appropriate.</p><p>Note that KDT is usually not a substitute for antiseizure medications. In one study, 86 percent of children on KDT remained on antiseizure medications as well, even when the number or doses were reduced in many cases [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3934375107"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>KDT is an effective treatment for patients with epilepsy, regardless of age or seizure type [<a href="#rid7">7</a>]. The major KDTs for the treatment of epilepsy are the classic (long-chain) ketogenic diet, the medium-chain triglyceride diet, the modified Atkins diet, the low glycemic index treatment, and the modified ketogenic diet. The composition of these diets is described below (see <a class="local">'Composition'</a> below); the evidence of their efficacy follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic ketogenic diet</strong> – In 2008, the first randomized controlled trial of the classic ketogenic diet, 145 children (ages 2 to 16 years) with drug-resistant epilepsy (failure of at least two antiseizure medications) were assigned to immediate implementation of the classic ketogenic diet or to a control group in whom implementation was delayed for three months [<a href="#rid9">9</a>]. At three months, 103 remained in the trial, 54 in the active treatment group. In these patients, treatment with the diet was associated with a lower mean percentage of baseline seizures (62 versus 137 percent) and a higher percentage with greater than 50 percent seizure reduction (38 versus 6 percent).</p><p></p><p class="bulletIndent1">A meta-analysis of 19 observational studies (1084 patients) found that after six months, approximately 60 percent of children started on the classic ketogenic diet had a greater than 50 percent seizure reduction, with 30 percent having greater than 90 percent seizure reduction [<a href="#rid10">10</a>]. Other meta-analyses and reviews have come to similar conclusions [<a href="#rid10">10-12</a>]. While more often considered a treatment in children rather than adults with epilepsy, the growing available (nonrandomized) evidence suggests that adults may also achieve benefit with the classic ketogenic diet [<a href="#rid13">13,14</a>]. Because the "classic" ketogenic diet must be strictly followed, adults are more commonly offered the modified Atkins diet, which is easier to use or follow. (See <a class="local">'Modified Atkins diet'</a> below.)</p><p></p><p class="bulletIndent1">Data are limited for the efficacy of the ketogenic diet in infancy, although use is growing in this age group due to availability of ketogenic formulas on the market. In an open-label trial, infants 1 to 24 months of age with drug-resistant epilepsy (having four or more seizures per week and prior treatment with two or more antiseizure medications) were randomly assigned to the classic ketogenic diet (n = 78) or to further antiseizure medication treatment (n = 58); data were available for 61 and 47 infants, respectively, in the modified intention-to-treat analysis [<a href="#rid15">15</a>]. During weeks six to eight, the median number of seizures per day was similar between the ketogenic diet and antiseizure medication groups, as was the responder rate (defined by a ≥50 percent improvement from baseline in seizure frequency). The number of serious adverse events was greater in the ketogenic diet group, although the proportion of infants affected was similar between groups. Trial limitations include small patient numbers, early stopping due to slow recruitment, and relatively high loss to follow-up.</p><p></p><p class="bulletIndent1">Some anecdotal and published evidence suggested that the classic ketogenic diet might be less effective in focal compared with generalized epilepsy [<a href="#rid16">16</a>]. However, there are many reports in which patients with focal epilepsy appear to respond to the classic ketogenic diet [<a href="#rid17">17-21</a>], and in the randomized clinical trial discussed above, the subgroups of focal versus generalized epileptic syndromes appeared to experience similar benefit [<a href="#rid9">9</a>]. On the other hand, patients with intractable focal epilepsy who are candidates for epilepsy surgery are more likely to achieve complete seizure remission with epilepsy surgery than with the classic ketogenic diet [<a href="#rid19">19,20</a>]. It is reasonable to attempt the classic ketogenic diet for children who are candidates for surgery, however, if the family or guardians are not ready or the child is very young. (See  <a class="medical medical_review" href="/z/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures", section on 'Epilepsy surgery'</a> and  <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">"Surgical treatment of epilepsy in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medium-chain triglyceride diet</strong> – A randomized controlled study found no difference in efficacy or tolerability between the classic ketogenic diet and the medium-chain triglyceride diet [<a href="#rid22">22</a>]; however, there may be individual differences. Most centers believe the MCT diet to be equivalent to the classic ketogenic diet, but it is still primarily used in England.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modified Atkins diet</strong> – The efficacy of the modified Atkins diet has been reported in more than 25 studies since 2003, including at least two randomized trials [<a href="#rid17">17,23-39</a>]. Overall, 175 of approximately 390 total reported patients (45 percent) have had at least a &gt;50 percent reduction in seizures after six months; of these, 96 (25 percent) had &gt;90 percent seizure reduction. When this cohort is specifically analyzed for adults, the results are less robust, with 26 of 90 (29 percent) having &gt;50 percent seizure reduction and 10 (11 percent) with &gt;90 percent seizure reduction.</p><p></p><p class="bulletIndent1">In one randomized trial in children, 102 patients ages 2 to 14 (mean age 5 years) with refractory epilepsy (daily seizures despite three or more antiseizure medications) were assigned to receive a modified Atkins diet or no dietary intervention for three months [<a href="#rid36">36</a>]. Four out of 50 patients discontinued the diet before the study endpoint (two due to frequent chest infections, one due to hyperammonemic encephalopathy, one due to patient and family preference). In an intention-to-treat analysis, treatment with the diet was associated with decreased mean seizure frequency as a percentage of baseline (59 versus 100 percent) and increased proportion of patients with &gt;50 percent reduction in seizure frequency (52 versus 12 percent). Five children (10 percent) became seizure-free on the diet, compared with none in the control arm. In a second trial of 160 patients (80 adults and 80 adolescents) with drug-resistant epilepsy, more patients had a &gt;50 percent reduction in seizure frequency at six months in the modified Atkins diet group compared with the control group (26.2 versus 2.5 percent, absolute risk reduction 23.7 percent, 95% CI 13.5–33.9) [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1">These results are similar to those reported for the classic ketogenic diet. When patients are able to remain on diet therapy for more than six months, rates of seizure reduction are also similar to those reported for the classic ketogenic diet [<a href="#rid35">35</a>]. A retrospective comparison of the two diets found that the classic ketogenic diet was more successful at three months (65 versus 20 percent achieved &gt;50 percent seizure reduction); at six months the difference was no longer statistically significant (41 versus 20 percent) [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1">A case series reviewed the experience of 27 patients treated with the modified Atkins diet who subsequently were switched to the ketogenic diet. Ten patients achieved additional benefit with the ketogenic diet; five of these became seizure-free [<a href="#rid40">40</a>]. Additional benefit occurred in a greater proportion of children with myoclonic-astatic epilepsy than other epilepsy syndromes. The five children who had no response to the Atkins diet did not respond to the ketogenic diet. This information suggests that the modified Atkins diet may represent a "low dose" of dietary treatment and the classic ketogenic diet a "high dose" (rather than two unique diets).</p><p></p><p class="bulletIndent1">Most experts perceive the modified Atkins diet as being equivalent and interchangeable with the classic ketogenic diet, and it is the primary diet for adolescents and adults [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low glycemic index treatment</strong> – This diet does not calculate fats but rather allows carbohydrates with glycemic indices &lt;55. However, it is still a high-fat diet, although high ketosis is not achieved. Results from a single center were the first to demonstrate early benefit with this diet in 74 patients [<a href="#rid41">41</a>]. Using an intent-to-treat analysis, 32 percent had a &gt;50 percent seizure reduction after three months of implementation.</p><p></p><p class="bulletIndent1">The low glycemic index treatment is typically used in adults, adolescents, and children with Angelman syndrome [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modified ketogenic diet (UK) </strong>– This diet has been used in United Kingdom and is essentially a low ratio classic ketogenic diet. In a one-year prospective cohort study, 42 adults with epilepsy (mean age 37 years) were started on the modified ketogenic diet [<a href="#rid43">43</a>]. Retention rates at 3, 6 and 12 months were 60, 43, and 29 percent, respectively. Improvement in seizure frequency was reported in 60 percent, while a &gt;50 percent reduction in seizure frequency in 38 percent, and worsening in seizure frequency in 30 percent. Discontinuation was most often attributed to adverse effects and dietary restrictiveness. In a clinical trial of 45 children who were randomly assigned to the classic or the modified ketogenic diet, there was no difference between groups for achieving a &gt;50 percent reduction in seizure frequency (approximately 45 percent in each group) [<a href="#rid44">44</a>]. However, the modified ketogenic diet was reported to be better tolerated and to have fewer adverse effects.</p><p></p><p class="headingAnchor" id="H186115"><span class="h2">Particularly responsive conditions</span><span class="headingEndMark"> — </span>A number of epilepsy syndromes, listed below, appear to be particularly responsive to the KDTs, identified by the expert panel as conditions with at least three publications from at least two ketogenic dietary centers that consistently reported at least a 20 percent or greater improvement in efficacy above the "norm" for KDT (ie, a 40 to 50 percent chance of ≥50 percent seizure reduction); that is, conditions with 60 to 70 percent responder rates [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3371401140"><span class="h3">Doose syndrome</span><span class="headingEndMark"> — </span>Doose syndrome (epilepsy with myoclonic-atonic seizures [EMAtS]), a generalized epilepsy of early childhood with a high frequency of intractability, has been reported to respond rapidly and often completely to KDT in a number of case series [<a href="#rid45">45-49</a>]. Up to 5 percent of patients with Doose syndrome may have glucose transporter 1 (GLUT-1) deficiency, another condition that responds to KDT as discussed below [<a href="#rid50">50</a>]. A three-center study of children with Doose syndrome found that KDT was associated with a 50 percent or greater reduction in seizures in 79 percent of cases, compared with only 26 percent with standard antiseizure medications [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H464015508"><span class="h3">Dravet syndrome</span><span class="headingEndMark"> — </span>Intractable epilepsy is one of the characteristics of Dravet syndrome along with intellectual delay and increased seizures with fever and heat. Observational studies suggest that KDTs may reduce seizure frequency in many of these patients, especially the atypical absence seizures noted in this condition. Since there are many newer antiseizure medications for Dravet syndrome, KDTs are less widely used than in the past but are valuable therapies to still consider. (See  <a class="medical medical_review" href="/z/d/html/108722.html" rel="external">"Dravet syndrome: Management and prognosis", section on 'Ketogenic dietary therapy'</a>.)</p><p class="headingAnchor" id="H3139284545"><span class="h3">GLUT-1 deficiency</span><span class="headingEndMark"> — </span>GLUT-1 deficiency syndrome, caused by <em>SLC2A1</em> mutations, is a genetic disorder characterized by impaired glucose transport across the blood brain barrier resulting in generalized epilepsy, developmental delay, and an associated movement disorder. It may also present with early-onset absence epilepsy. KDT is the most effective first-line treatment for this disorder and provides ketones as an alternative energy source for the brain [<a href="#rid50">50-53</a>]. In one study of 92 children, 95 percent had &gt;50 percent seizure reduction after initiation of KDT and 80 percent had &gt;90 percent seizure reduction [<a href="#rid54">54</a>]. Two-thirds of the patients were not on antiseizure medications. Two other studies have reported similar efficacy rates [<a href="#rid55">55,56</a>].</p><p>While seizures typically remit with this treatment, the effects on neurodevelopment are less apparent [<a href="#rid23">23,24</a>]. However, the diagnosis of GLUT-1 deficiency is often delayed, and developmental outcomes may be better with early initiation of dietary therapy [<a href="#rid57">57,58</a>]. Supplementation with <a class="drug drug_general" data-topicid="128893" href="/z/d/drug information/128893.html" rel="external">triheptanoin</a>, a medium-chain triglyceride, is also under investigation as a potential novel therapy for this disorder [<a href="#rid59">59</a>], but most GLUT-1 experts do not advocate it as a substitute for the ketogenic diet at this time. (See  <a class="medical medical_review" href="/z/d/html/14450.html" rel="external">"Childhood absence epilepsy", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H309681881"><span class="h3">Infantile epileptic spasms syndrome</span><span class="headingEndMark"> — </span>A number of large observational studies have shown that the KDTs may control infantile epileptic spasms syndrome in patients refractory to first-line treatments. They are widely used therapies after first-line treatment with hormonal therapy or <a class="drug drug_general" data-topicid="10115" href="/z/d/drug information/10115.html" rel="external">vigabatrin</a> for Dravet syndrome. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6186.html" rel="external">"Infantile epileptic spasms syndrome: Management and prognosis", section on 'Ketogenic diet'</a>.)</p><p class="headingAnchor" id="H222486930"><span class="h3">Pyruvate dehydrogenase deficiency</span><span class="headingEndMark"> — </span>KDT may also serve to provide an alternative energy source for the brain in pyruvate dehydrogenase deficiency, a mitochondrial disease characterized by lactic acidosis, severe neurologic impairments, and occasionally, intractable epilepsy [<a href="#rid60">60,61</a>]. In uncontrolled reports, patients on the ketogenic diet appear to have an improved neurologic outcome (eg, cognition, vision) [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H64153744"><span class="h3">Tuberous sclerosis complex</span><span class="headingEndMark"> — </span>Many patients with tuberous sclerosis complex are refractory to medical treatment but have multiple tubers that can be epileptogenic making surgery impossible. In these patients, KDT may help control seizures and should be considered along with other nonpharmacologic interventions. (See  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Epilepsy'</a>.)</p><p class="headingAnchor" id="H109555677"><span class="h3">Gastrostomy- or formula-fed children</span><span class="headingEndMark"> — </span>Poor adherence to the strict diet is a major limiting factor in the effective use of the KDTs. This is much less of a concern in patients who receive all of their nutrition via formula or gastrostomy feedings. In one case series, 12 patients with intractable epilepsy and a static encephalopathy were maintained on the ketogenic diet administered via a gastrostomy tube; only two patients did not improve; six patients achieved a more than 90 percent reduction in seizures [<a href="#rid63">63</a>]. A retrospective study found that 61 children who were administered the KDT via formula (31 formula fed infants; 30 gastrostomy tube fed children) had better rates of &gt;90 percent seizure remission with the diet than children administered the diet through solid food: 59 versus 27 percent [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H3132966125"><span class="h3">Super-refractory status epilepticus</span><span class="headingEndMark"> — </span>There have been multiple case reports of KDT successfully treating prolonged, medically refractory nonconvulsive and focal status epilepticus in adults and children [<a href="#rid65">65-67</a>]. One case series describes efficacious use of KDT in seven of nine patients with febrile infection-related refractory epileptic encephalopathy (FIRES) [<a href="#rid68">68</a>]. An additional case report describes successful use of the modified Atkins diet in two children with nonconvulsive status epilepticus [<a href="#rid69">69</a>]. These cases all used ketogenic formulas provided through enteral (eg, gastric) tubes to administer KDT and achieve ketosis. In a prospective multicenter study of 15 patients with super refractory status epilepticus (ie, persisting for 24 hours or more despite appropriate anesthetic treatment, or returning after withdrawal of anesthetic agents), 14 patients completed ketogenic dietary treatment, and status resolved in 11 (73 percent) at a median of five days after starting ketogenic diet [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a> and  <a class="medical medical_review" href="/z/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management"</a>.)</p><p class="headingAnchor" id="H2682692837"><span class="h3">Others</span><span class="headingEndMark"> — </span>Other conditions identified by the expert panel as particularly responsive to KDT are the following [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Angelman syndrome (see  <a class="medical medical_review" href="/z/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '15q11-13 maternal deletion syndrome (Angelman syndrome)'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Complex I mitochondrial disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Ohtahara syndrome (see  <a class="medical medical_review" href="/z/d/html/139238.html" rel="external">"Overview of infantile epilepsy syndromes", section on 'Early infantile developmental and epileptic encephalopathy'</a>)</p><p></p><p class="headingAnchor" id="H1298415794"><span class="h2">Moderately responsive conditions</span><span class="headingEndMark"> — </span>In other conditions, KDT may be at least moderately beneficial, based upon lower-quality data or reports suggesting that the response is similar to but no better than the "norm" (ie, a 40 to 50 percent chance of ≥50 percent seizure reduction) [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rett syndrome</strong> – KDT may improve intractable seizures in patients with Rett syndrome. However, in view of the frequent occurrence of growth failure in this syndrome, a ketogenic diet should be used with some caution. (See  <a class="medical medical_review" href="/z/d/html/109840.html" rel="external">"Rett syndrome: Treatment and prognosis", section on 'Seizures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Landau-Kleffner syndrome</strong> – This epilepsy syndrome, which is now encompassed by the term DEE-SWAS, is sometimes associated with intractable epilepsy that may benefit from KDT [<a href="#rid71">71</a>]. The value for improving the EEG in this condition is somewhat controversial, however. (See  <a class="medical medical_review" href="/z/d/html/6162.html" rel="external">"Epilepsy syndromes in children", section on 'Developmental and epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lennox-Gastaut syndrome (LGS)</strong> – This condition has many causes and is characterized by intractable epilepsy with multiple seizure types, especially tonic seizures; KDT appears to be helpful in many cases. (See  <a class="medical medical_review" href="/z/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absence epilepsy </strong>– Children with absence epilepsy may respond to KDT when antiseizure medications are incompletely effective. An ongoing clinical trial is comparing the modified Atkins diet with <a class="drug drug_general" data-topicid="9440" href="/z/d/drug information/9440.html" rel="external">ethosuximide</a> for the treatment of new-onset absence seizures. (See  <a class="medical medical_review" href="/z/d/html/14450.html" rel="external">"Childhood absence epilepsy", section on 'Patients who fail or do not tolerate first-line therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Juvenile myoclonic epilepsy</strong> – In one case series of eight adolescents and adults with refractory juvenile myoclonic epilepsy, five patients had &gt;50 percent seizure reduction after three months of a modified Atkins diet [<a href="#rid37">37</a>]. This diet may be considered as an alternative to <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> for adolescent or adult women with refractory juvenile myoclonic epilepsy who wish to avoid the teratogenicity of valproate. (See  <a class="medical medical_review" href="/z/d/html/17192.html" rel="external">"Juvenile myoclonic epilepsy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – Additional epilepsy conditions that may benefit from KDT are [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adenylosuccinate lyase deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Cyclin-dependent kinase-like 5 (CDKL5) encephalopathy</p><p class="bulletIndent2"><span class="glyph">•</span>Cortical malformations (see  <a class="medical medical_review" href="/z/d/html/6199.html" rel="external">"Seizures and epilepsy in children: Classification, etiology, and clinical features", section on 'Neurodevelopmental lesions'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Epilepsy of infancy with migrating focal seizures</p><p class="bulletIndent2"><span class="glyph">•</span>Epileptic encephalopathy with continuous spike-and-wave during sleep (see  <a class="medical medical_review" href="/z/d/html/6162.html" rel="external">"Epilepsy syndromes in children", section on 'Developmental and epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS)'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Lafora body disease</p><p></p><p class="headingAnchor" id="H21468812"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Fasting or implementation of KDT in individuals with inborn errors of metabolism that affect the transport or oxidation of long-chain fatty acids can lead to a devastating catabolic crisis. KDT can also exacerbate acute intermittent porphyria.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absolute contraindications</strong> to all forms of KDT include [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary carnitine deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Carnitine palmitoyltransferase I or II deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Carnitine translocase deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Fatty acid beta-oxidation defects</p><p class="bulletIndent2"><span class="glyph">•</span>Medium-chain acyl dehydrogenase deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Long-chain acyl dehydrogenase deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Short-chain acyl dehydrogenase deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Long-chain 3-hydroxyacyl-CoA deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Medium-chain 3-hydroxyacyl-CoA deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Pyruvate carboxylase deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Porphyria</p><p></p><p class="bulletIndent1">Carnitine cycle disorders and long-, medium-, and short-chain fatty acid oxidation disorders are reviewed separately (see  <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">"Specific fatty acid oxidation disorders"</a>), as are pyruvate carboxylase deficiency (see  <a class="medical medical_review" href="/z/d/html/5801.html" rel="external">"Causes of hypoglycemia in infants and children", section on 'Pyruvate carboxylase deficiency'</a>) and porphyria. (See  <a class="medical medical_review" href="/z/d/html/7101.html" rel="external">"Porphyrias: An overview"</a>.)</p><p></p><p class="bulletIndent1">Patients with clinical features suggesting one of these diagnoses (eg, cardiomyopathy, hypotonia, exercise intolerance, myoglobinuria, easy fatigability) should be tested in order to exclude these conditions [<a href="#rid7">7</a>]. Recommended tests are included in the table  (<a class="graphic graphic_table graphicRef67745" href="/z/d/graphic/67745.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent1">By contrast, patients with mitochondrial respiratory chain complex defects and epilepsy have been safely and effectively treated with KDT [<a href="#rid72">72</a>]. (See <a class="local">'Particularly responsive conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relative contraindications</strong> to KDT include the following [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inability to maintain adequate nutrition</p><p class="bulletIndent2"><span class="glyph">•</span>Inability of parent or caregiver to comply with dietary therapy</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a> concurrent use (risk of propofol infusion syndrome may be higher)</p><p></p><p class="bulletIndent1">These conditions may make the diet difficult to implement, interfere with compliance, or increase the risk of adverse events.</p><p></p><p class="bulletIndent1">In addition, patients with intractable focal epilepsy who are candidates for epilepsy surgery are likely to have a better response to epilepsy surgery than to KDT [<a href="#rid19">19</a>]. An electroencephalogram (EEG) and magnetic resonance imaging (MRI) are useful in the evaluation of potential epilepsy surgery candidates, but are likely to have been performed prior to consideration of KDT. However, a trial of KDT prior to surgery is an individual family/caregiver decision and should not be necessarily discouraged. (See  <a class="medical medical_review" href="/z/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures", section on 'Epilepsy surgery'</a> and  <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">"Surgical treatment of epilepsy in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3939922608"><span class="h1">IMPLEMENTATION</span></p><p class="headingAnchor" id="H4006605622"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Prior to starting KDT, it is important to counsel patients, families, guardians, and caregivers about the implications and potential medical concerns associated with strict KDT, including anticipated seizure reduction, concomitant antiseizure medication use, and the psychosocial issues that may impact implementation [<a href="#rid7">7</a>]. When it comes to the diet, a discussion must include the cost and time involved in preparing special meals for the child or adult patient, avoidance of carbohydrates, the complexity of diet management, the importance of strict adherence to the diet, the need for additional supplements (see <a class="local">'Supplementation'</a> below), and potential adverse effects (see <a class="local">'Adverse effects'</a> below). If there is disagreement between parents or caregivers about using the diet, it is probably not worth starting.</p><p>It is important to assess potential food allergies or intolerances as well as cultural and religious dietary needs. A review of a three-day food record can also be helpful in identifying potential problems. However, most religions and cultures can be successfully accommodated with KDT.</p><p>Components of the pretreatment evaluation and laboratory studies are provided in the table  (<a class="graphic graphic_table graphicRef120638" href="/z/d/graphic/120638.html" rel="external">table 2</a>) [<a href="#rid7">7</a>]. Patients must be screened for contraindications and evaluated for comorbid conditions that may complicate therapy. (See <a class="local">'Contraindications'</a> above.)</p><p>There is one more pretreatment concern: certain medical conditions may be aggravated by the diet. These include a history of kidney stones, hypercholesterolemia, liver disease, gastroesophageal reflux, constipation, cardiomyopathy, and chronic metabolic acidosis. A renal ultrasound and nephrology consult are recommended if there is a personal or family history of kidney stones. These conditions do not preclude the diet’s use, but make it more difficult. Prior history of pancreatitis or elevated cholesterol should be discussed at length with the family before initiating the diet.</p><p class="headingAnchor" id="H113261215"><span class="h2">Diet selection</span><span class="headingEndMark"> — </span>The major KDTs for the treatment of epilepsy are the classic (long-chain) ketogenic diet, the medium-chain triglyceride diet, the modified Atkins diet, the low glycemic index treatment, and the modified ketogenic diet. The choice of a particular diet is individualized and often at the discretion of the parent. Most centers agree, however, that infants and children under two years of age should use the classic ketogenic diet, whereas adolescents and adults may have improved compliance if the modified Atkins diet or low glycemic index treatment is chosen.</p><p class="headingAnchor" id="H2685087152"><span class="h2">Composition</span></p><p class="headingAnchor" id="H1119266321"><span class="h3">Classic ketogenic diet</span><span class="headingEndMark"> — </span>In the classic ketogenic diet, fat comes primarily from long-chain triglycerides obtained through standard foods; protein intake is based on that required for growth; and carbohydrates are restricted. The classic ketogenic diet consists of four parts fat to one part protein and carbohydrate (ie, 4:1 lipid to nonlipid ratio) [<a href="#rid7">7</a>]. Fat provides 90 percent of the calories. At most centers, dietitians match calories to the pre-ketogenic diet baseline. In the past, total calories were restricted to 80 to 90 percent of recommended values for age, but this did not result in clear benefit [<a href="#rid73">73,74</a>]. Modification of the diet to a somewhat lower fat content (3:1 lipid to nonlipid ratio from the classic 4:1 ratio) improves tolerability of the diet, but may reduce its efficacy during the initial three months [<a href="#rid75">75</a>].</p><p>Alternatively, the diet can be given as a liquid-based formula to bottle-fed infants and enterally fed patients. There are a number of commercially available products. Because the diet is easy to administer in this form, compliance and efficacy are generally excellent in this population [<a href="#rid63">63,64</a>]. (See <a class="local">'Particularly responsive conditions'</a> above.)</p><p class="headingAnchor" id="H3504539945"><span class="h3">Medium-chain triglyceride diet</span><span class="headingEndMark"> — </span>In an alternative form of the classic ketogenic diet, medium-chain triglycerides provided in an oil supplement (eg, coconut oil) are utilized as a major fat source [<a href="#rid9">9</a>]. These medium-chain triglycerides yield more ketones, are more efficiently absorbed, and are carried directly to the liver. As a result, less total fat is needed in the diet and more protein and carbohydrates can be allowed. The medium-chain triglyceride diet is widely used in England because the highly ketogenic nature of medium-chain triglyceride oils allows for additional carbohydrates. Many centers will also add medium-chain triglyceride oils to the classic ketogenic diet as a supplement (eg, 5 to 10 mL several times a day).</p><p>The traditional medium-chain triglyceride diet derives 60 percent of the energy from medium-chain triglycerides [<a href="#rid7">7</a>]. In some children, this needs to be reduced to 30 to 50 percent in order to minimize gastrointestinal symptoms, with the resulting decrement in energy source to be made up from long-chain fats.</p><p>Medium-chain triglycerides should be given with each meal or evenly divided up between several smaller meals in order to improve tolerance.</p><p class="headingAnchor" id="H1923524957"><span class="h3">Modified Atkins diet</span><span class="headingEndMark"> — </span>The modified Atkins diet is an alternative KDT designed to mimic some aspects of the classic ketogenic diet but allow more ad lib protein, fluids, and calories [<a href="#rid25">25,76</a>].</p><p>The diet is initiated as an outpatient without a fast. Carbohydrates are initially restricted to 20 grams per day with patients counseled to increase their use of high-fat foods (at the expense of protein). When implemented, most parents will provide an approximately 1:1 to 2:1 lipid to nonlipid ratio (although there is no weighing and measuring of foods recommended in this regimen) [<a href="#rid76">76</a>]. A ketogenic liquid supplement (KetoCal shake) can be used during the first month to increase the ketogenic ratio [<a href="#rid77">77</a>]. All children are started on a multivitamin and calcium, and lab studies are obtained identically to the classic ketogenic diet. After one to three months, the carbohydrate restrictions can be loosened and/or antiseizure medications reduced as clinically indicated.</p><p>This less restrictive diet has been used successfully in adults who are not typically offered the classic ketogenic diet [<a href="#rid26">26,27</a>], in countries with limited financial and dietitian resources [<a href="#rid28">28</a>], in children on the classic ketogenic diet for many years who desire fewer restrictions [<a href="#rid25">25</a>], and as an early treatment for epilepsy before intractability is established [<a href="#rid76">76</a>]. One center reported that the modified Atkins diet could be successfully maintained in selected adults using electronic communication (email) rather than in-person clinic visits [<a href="#rid78">78</a>]. This may be particularly useful in resource-poor regions of the world.</p><p>Ketosis will occur with the modified Atkins diet and may correlate with seizure control, but perhaps only initially, during the first month [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H2769646761"><span class="h3">Low glycemic index treatment</span><span class="headingEndMark"> — </span>An even less restrictive KDT, the low glycemic index diet restricts carbohydrates to 40 to 60 grams per day, does not restrict fluids or protein, and loosely monitors fat and calories [<a href="#rid79">79</a>]. It is started as an outpatient without a fasting period. As with the other KDTs, most children eat significantly more fat on this regimen than they did before. Unlike the modified Atkins diet, the type of carbohydrates is important in the low glycemic index diet, with only carbohydrates with low glycemic indices (&lt;50) allowed. These carbohydrates include strawberries and whole grain breads as opposed to potatoes, white bread, and most citrus fruits. In patients on this diet, there is nearly no serum ketosis noted.</p><p class="headingAnchor" id="H3773500516"><span class="h3">Modified ketogenic diet</span><span class="headingEndMark"> — </span>The modified ketogenic diet, created in United Kingdom [<a href="#rid80">80</a>], uses a 1:1 ketogenic ratio (lower than normal), yet still monitors grams of fat, protein, and carbohydrates using a gram scale. It targets approximately 75 percent of calories from fat, 20 percent from protein, and 5 percent from carbohydrate, and is started at home. Although gram scales are used, simple food lists and recipes are provided to make it easier.</p><p class="headingAnchor" id="H21468851"><span class="h2">Starting treatment</span><span class="headingEndMark"> — </span>Ideally, KDT should be supervised by a trained dietitian and neurologist in an epilepsy center with expertise in this form of therapy. Antiseizure medications should be switched to carbohydrate-free preparations (preferably tablets rather than liquid or chewable formulations). Dosing regimens are typically left unchanged for at least the first month of KDT [<a href="#rid81">81</a>]. It is also important to reduce or eliminate carbohydrates in medications where possible [<a href="#rid82">82</a>]. Another strategy is to compensate for potential carbohydrates in medications by increasing the ketogenic ratio. In one small case-control study, children remained on liquid antiseizure medications, compensated by an increased ketogenic ratio; these children had similar outcomes in achieving large ketosis, weight gain, and seizure reduction compared with controls on tablet formulations [<a href="#rid83">83</a>]. (See <a class="local">'Antiseizure medication management'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>The classic ketogenic diet and the medium-chain triglyceride diet</strong> are often started in the hospital without a fast period, but alternative approaches are recognized:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inpatient versus outpatient </strong>– The classic ketogenic diet is most often started in the hospital, which provides for close observation and rapid medical interventions if needed [<a href="#rid7">7</a>]. One of the most important reasons for the admission is to educate the parents and caregivers. Most hospitals will schedule lectures and teaching sessions during the admission. After an average hospital duration of three to four days, the child is discharged home.</p><p></p><p class="bulletIndent2">Outpatient initiation of the classic ketogenic diet is an option for select children (≥12 months of age) who live close to medical care [<a href="#rid7">7</a>]. For outpatient initiation, children must first undergo metabolic testing and receive appropriate education about the diet. Some centers will initiate the classic ketogenic diet as an outpatient with classes held in various settings [<a href="#rid73">73</a>]. Although only 20 percent of an expert consensus panel routinely starts the classic ketogenic diet as an outpatient, the majority (92 percent) felt that it was possible to do this in select situations [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fasting versus nonfasting </strong>– The classic ketogenic diet was traditionally started following a 24-hour fasting period, but fasting is now considered optional [<a href="#rid7">7</a>]. Fasting may be appropriate when more rapid seizure control is needed. However, the initial fasting period is not required for long-term seizure control and increases the risk for hypoglycemia and lethargy [<a href="#rid84">84,85</a>]. We suggest avoiding fasting in children younger than two years and in older children who are poor eaters, those with multiple medical comorbidities, and children who have limited ability to communicate complaints of fatigue or nausea. In one study, 80 percent of children admitted for the classic ketogenic diet had some (often mild) side effects, typically resolving with minor interventions, but they can be more severe in those younger [<a href="#rid85">85</a>]. A randomized study that compared initial fasting with a more gradual initiation period found that there was less hypoglycemia, acidosis, or weight loss with a gradual approach, but the incidence of vomiting was unchanged [<a href="#rid84">84</a>]. Fasting does appear to lead to a more rapid onset of ketosis and seizure control, however [<a href="#rid86">86,87</a>].</p><p></p><p class="bulletIndent2">The favored approach at many centers is to begin with full calories. This can be accomplished by gradually increasing the lipid to nonlipid ratio daily from 1:1, 2:1, 3:1, and finally to 4:1 to help the patient adapt to the higher fat concentration [<a href="#rid84">84</a>]. The classic ketogenic diet can also be started at full calories and a ratio of 4:1 on the first day; retrospective evidence suggests this approach does not reduce efficacy or increase adverse effects [<a href="#rid74">74</a>]. Alternatively, the diet can be started at a set ratio (eg, 4:1) and calories (not ratio) increased daily.</p><p></p><p class="bulletIndent2">During the first one to two days of hospitalization, serum glucose is typically monitored several times a day (eg, before meals); small quantities of orange juice are provided if serum glucose falls below 30 mg/dL [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The modified Atkins diet and the low glycemic index treatment</strong> are usually started in the outpatient setting without a fasting period but with group teaching sessions to help caregivers learn how to manage these diets at home [<a href="#rid7">7</a>]. (See <a class="local">'Modified Atkins diet'</a> above and <a class="local">'Low glycemic index treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H3204586587"><span class="h2">Supplementation</span><span class="headingEndMark"> — </span>All children on KDTs are started routinely on a carbohydrate-free multivitamin with minerals (including <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a>), calcium, and vitamin D supplement [<a href="#rid7">7</a>]. At Johns Hopkins and other centers, based on evidence for reduced kidney stone risk, all children are also started on a daily <a class="drug drug_general" data-topicid="10225" href="/z/d/drug information/10225.html" rel="external">potassium citrate</a> supplement (2 mEq/kg per day) [<a href="#rid88">88</a>]. Recommended and optional supplements for children are listed in the table  (<a class="graphic graphic_table graphicRef120630" href="/z/d/graphic/120630.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H2470708287"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H1807894339"><span class="h2">Burden</span><span class="headingEndMark"> — </span>Parents and caregivers should be counseled as to the common, occasional, and rare adverse effects that can happen in the short-term when using KDTs. Fortunately, most adverse effects are predictable, often preventable, and only uncommonly in themselves lead to diet discontinuation [<a href="#rid7">7</a>]. Adverse effects and intolerance of the food restrictions are important to address early in the course of dietary therapy to prevent these issues from leading to premature discontinuation [<a href="#rid89">89,90</a>].</p><p class="headingAnchor" id="H3714060266"><span class="h2">Common adverse effects</span><span class="headingEndMark"> — </span>Relatively common adverse effects of all forms of KDT include [<a href="#rid7">7,85</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal symptoms</strong> – Diarrhea, constipation, nausea, vomiting, and exacerbation of gastroesophageal reflux are among the most common side effects, occurring in more than half of children on the ketogenic diet [<a href="#rid7">7,35,36,85,91</a>]. These are generally managed symptomatically with proton pump inhibitors, laxatives, and other treatments as needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dyslipidemia</strong> – While abnormal lipid parameters are frequently seen, significant hypercholesterolemia and hypertriglyceridemia are less common [<a href="#rid35">35,90,92-96</a>]. Most levels improve spontaneously even without dietary or other intervention, and only a minority of patients require medication.</p><p></p><p class="bulletIndent1">While some centers are hesitant to use the KDT in children with baseline hyperlipidemia, there is evidence that dietary modifications can control lipid levels [<a href="#rid93">93,95,96</a>]. These modifications include increasing the consumption of medium-chain triglycerides and olive oil; adding omega-3 fatty acid or <a class="drug drug_general" data-topicid="10109" href="/z/d/drug information/10109.html" rel="external">carnitine supplementation</a> while reducing trans fat, saturated fat, and cholesterol; decreasing the lipid to nonlipid ratio of the diet; avoiding fatty meats, egg yolk, cream, butter, animal fat, palm oil and coconut oil; and using an exclusively formula-based ketogenic diet.</p><p></p><p class="bulletIndent1">Atherogenic consequences of KDT, if any, are not known, but do not appear to happen in children who are followed years after KDT has been discontinued [<a href="#rid7">7</a>]. Studies are underway in adults on KDT specifically to investigate lipid abnormalities [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoglycemia</strong> – One or more episodes of hypoglycemia occur in approximately 25 percent of patients during the initiation week [<a href="#rid85">85</a>]. Pre-diet fasting may increase risk for hypoglycemia and lethargy, particularly in younger children (&lt;2 years of age). (See <a class="local">'Starting treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other laboratory abnormalities</strong> – Hyperuricemia, hypoproteinemia, hypomagnesemia, hyponatremia, hepatitis, and metabolic acidosis are sometimes seen and should be monitored for (see <a class="local">'Follow-up and monitoring'</a> below), but are usually minor [<a href="#rid90">90</a>]. Metabolic acidosis requiring treatment may be more common in children who are also taking <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> or <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a> [<a href="#rid98">98</a>]. Rare cases of severe hypercalcemia have been reported [<a href="#rid99">99</a>]. A study of 66 children with drug-resistant epilepsy found that thyroid hormone levels were unchanged with KDT [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth failure</strong> – Most children on KDT fall into lower height and weight percentiles [<a href="#rid101">101-104</a>]. Younger children on KDT for longer periods of time appear to be the most at risk. In one small series, height velocity was most affected in those with the most pronounced ketosis [<a href="#rid105">105</a>]. The higher protein content in the medium-chain triglyceride diet does not appear to ameliorate this [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carnitine deficiency </strong>– Carnitine levels typically decline in the first months on KDT; however, carnitine deficiency is not common (&lt;20 percent) [<a href="#rid90">90,107</a>]. Levels typically stabilize or improve spontaneously without supplementation. The expert panel recommended supplementation for those with low carnitine levels who are symptomatic with fatigue and lethargy (82 percent agreement) [<a href="#rid7">7</a>]. Only 16 percent of centers automatically use <a class="drug drug_general" data-topicid="10109" href="/z/d/drug information/10109.html" rel="external">carnitine supplementation</a> in all children on the ketogenic diet [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone disease</strong> – Osteopenia, osteoporosis, and bone fractures are a concern for children maintained on KDTs, as they are for children on chronic antiseizure medications [<a href="#rid90">90,102,108,109</a>]. Prophylactic supplementation with calcium and vitamin D is mandatory for all children on KDTs, but sometimes fails to prevent continued bone loss. Although there is no consensus, many centers screen children who are on KDTs for two years or more with dual-energy x-ray absorptiometry (DXA) scans to evaluate for osteopenia [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">"Overview of dual-energy x-ray absorptiometry"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrolithiasis</strong> – Kidney stones may occur with KDTs in as many as 7 percent of children [<a href="#rid90">90,110</a>]; if fluid intake is normal, the incidence is likely lower, and in one study was reduced to less than 1 percent with the addition of a <a class="drug drug_general" data-topicid="10225" href="/z/d/drug information/10225.html" rel="external">potassium citrate</a> supplement [<a href="#rid88">88</a>]. The risk for kidney stones is highest in those with baseline urologic abnormalities or a personal or family history of nephrolithiasis [<a href="#rid110">110</a>]. Slightly more than half (56 percent) of the expert panel use potassium citrate in all patients empirically on KDT to prevent stones [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selenium</strong><strong> deficiency</strong> – Selenium deficiency has been found in up to approximately 50 percent of children on KDTs [<a href="#rid111">111</a>]. Selenium deficiency has rarely produced an irreversible cardiomyopathy and sudden death in children on KDT [<a href="#rid112">112-114</a>]. Most centers check selenium levels; repletion with multivitamin with minerals including <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> is the most common strategy to avoid selenium deficiency [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutropenia</strong> – A retrospective report of 102 children with epilepsy found that KDT was associated with an increased prevalence of neutropenia, generally mild, beginning at approximately six months of treatment and affecting up to 25 percent of patients [<a href="#rid115">115</a>]. However, there was no association of neutropenia with clinically significant infection.</p><p></p><p class="headingAnchor" id="H3655316273"><span class="h2">Less common or rare adverse effects</span><span class="headingEndMark"> — </span>Less common adverse effects of KDTs include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac abnormalities</strong> – As noted above, cardiomyopathy and prolonged QT intervals have been described in patients on KDT with and without <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> deficiency [<a href="#rid116">116</a>]; in the absence of selenium deficiency, the mechanism of cardiac abnormalities is unknown [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancreatitis</strong> – Pancreatitis has been reported in a few children on KDT [<a href="#rid90">90,117,118</a>]. Most cases, but not all, had another risk factor for pancreatitis, usually <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular changes</strong> – Several studies have documented a transient decrease in carotid distensibility in children on KDTs [<a href="#rid119">119,120</a>]. The clinical relevance of this is unclear.</p><p></p><p class="headingAnchor" id="H1412495433"><span class="h2">Resolution with diet discontinuation</span><span class="headingEndMark"> — </span>Once KDT is discontinued, most of the adverse effects resolve. In a follow-up study of 101 children who had discontinued the diet at a median of six years prior, height, weight, cholesterol, and food preferences were all normal [<a href="#rid121">121</a>]. There was no increased risk of late reported cardiovascular disease, bone fractures, or kidney stones. Most patients were eating normal foods years later as well.</p><p class="headingAnchor" id="H21468888"><span class="h1">ANTISEIZURE MEDICATION MANAGEMENT</span><span class="headingEndMark"> — </span>KDTs generally do not significantly alter serum levels of the most commonly used antiseizure medications, and there are no particular antiseizure medications to avoid with KDTs [<a href="#rid7">7</a>]. Implementation of KDT was not associated with altered plasma concentrations of antiseizure medications in one case series of 51 children, suggesting that no dose adjustments or additional monitoring of drug levels beyond what is otherwise required is necessary in children on KDT [<a href="#rid122">122</a>]. However, more recent evidence in adults may indicate levels may fluctuate with KDT [<a href="#rid123">123</a>].</p><p>If seizure control is obtained on KDT, antiseizure medication withdrawal can begin as early as the first month of KDT. A slow, cautious taper is advised for medications like <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> and benzodiazepines since rapid changes in these drugs can result in medication-withdrawal seizures [<a href="#rid7">7</a>].</p><p>KDT should be considered an adjunctive therapy for seizures; most patients on KDT remain on at least one antiseizure medication. In a retrospective series of 81 children, antiseizure medications were tapered during the first six months on KDT in 65 percent and within the first month on the diet in 37 percent [<a href="#rid124">124</a>]. Antiseizure medications were successfully eliminated in approximately 20 percent of patients. Transient worsening was more likely when the tapered drug was <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> or a benzodiazepine.</p><p>It is unknown if any particular antiseizure medications modify the efficacy of KDT, and data are scarce. In one report of 115 patients on KDT, a greater than 50 percent reduction in seizure frequency was more common in patients on <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>, while those on <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> were less likely to achieve this benefit [<a href="#rid125">125</a>]. Another study of 71 children suggested lower efficacy of KDT with combined use of <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> [<a href="#rid126">126</a>]. The results of these small retrospective studies are not conclusive.</p><p class="headingAnchor" id="H606630997"><span class="h1">FOLLOW-UP AND MONITORING</span><span class="headingEndMark"> — </span>Once children are started on KDT, they should be seen in clinic for follow-up at one month and then at 3, 6, 9, and 12 months during the first year of treatment [<a href="#rid7">7</a>]. Thereafter, follow-up should be every six months. Infants and those at higher risk for nutritional deficiency should have more frequent follow-up (at times monthly). Each visit provides an opportunity to adjust KDT and/or antiseizure medications if needed in order to improve seizure control and reduce adverse effects [<a href="#rid127">127</a>]. Email and phone contact in between clinic appointments is also recommended.</p><p>A clinical response to KDT is quick, usually within a few weeks [<a href="#rid18">18,87</a>]. Its efficacy can generally be established in individual patients within two to three months of initiation.</p><p>Routine monitoring recommendations are outlined in the table  (<a class="graphic graphic_table graphicRef120624" href="/z/d/graphic/120624.html" rel="external">table 4</a>). Calorie intake, height, and weight are monitored at each visit. Calorie intake should be adjusted for excessive weight loss or gain. Laboratory studies, including complete blood count with platelets, comprehensive metabolic profile, fasting lipid profile, calcium, vitamin D, and magnesium are recommended every three months during the first year of therapy and every 6 to 12 months thereafter [<a href="#rid7">7</a>]. Additional laboratory studies may be useful for select patients, including serum <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a>, zinc, beta-hydroxybutyrate levels, as well as renal ultrasounds and dual-energy x-ray absorptiometry (DXA) scans  (<a class="graphic graphic_table graphicRef120624" href="/z/d/graphic/120624.html" rel="external">table 4</a>). European guidelines recommend monitoring serum beta-hydroxybutyrate levels for infants [<a href="#rid128">128</a>].</p><p>Measurement of urine ketones by parents is recommended several times per week to ensure the diet is being managed correctly, in a manner analogous to following antiseizure medication levels [<a href="#rid7">7</a>]. The value of serum ketone monitoring is unclear.</p><p>Some children may require laxatives if constipation is a problem, and/or extra <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a>, salt, or carnitine, if they develop relevant abnormal laboratory parameters. The ketogenic ratio can be adjusted if there is loss of seizure control or decreased ketosis.</p><p>Monitoring for metabolic acidosis is suggested for patients on KDT who are taking carbonic anhydrase inhibitors (eg, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> and especially <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>) particularly in the first weeks/months after diet initiation [<a href="#rid98">98</a>]. While the combination of carbonic anhydrase inhibitors and the KDTs might be expected to increase the risk of kidney stones, this does not appear to be the case. In one series of 221 children on the diet, kidney stones were no more common in children on these antiseizure medications than on any other regimen [<a href="#rid110">110</a>].</p><p>The use of <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> in the setting of KDT may increase the risk of secondary carnitine deficiency [<a href="#rid117">117,129</a>], and there are rare reports of hepatotoxicity [<a href="#rid90">90,130,131</a>]. Increased monitoring of liver function tests and carnitine levels may be prudent in children on this therapeutic combination. In at least one case report of hepatic dysfunction arising in a child taking valproate, liver enzymes normalized when the drug was stopped and the diet was able to be resumed [<a href="#rid130">130</a>]. Pancreatitis has been reported a few cases of children on the ketogenic diet who were also taking valproate [<a href="#rid90">90,117,118</a>].</p><p class="headingAnchor" id="H4048242294"><span class="h1">DIET DURATION AND DISCONTINUATION</span><span class="headingEndMark"> — </span>Observational studies suggest that if successful, KDT usually will result in seizure reduction within two to three months [<a href="#rid87">87</a>]. We therefore recommend discontinuing KDT as a treatment failure only after it has been used for at least three months [<a href="#rid7">7</a>].</p><p>For patients who do experience benefit, there are no clear minimum or maximum duration periods for KDT, and the timing should be individualized [<a href="#rid7">7</a>]. In children who benefit from the diet, we re-evaluate the relative value of KDT after one and two continuous years of use, especially in those who have become seizure-free [<a href="#rid7">7</a>]. Eighty percent of those who discontinue KDT after two years of seizure freedom will continue to remain seizure-free [<a href="#rid132">132</a>]. Many centers obtain electroencephalography (EEG) to help inform the decision about withdrawing KDT [<a href="#rid7">7</a>]. Adults doing well with KDT may choose to remain on treatment for much longer, as their epilepsy is less likely to spontaneously improve.</p><p>The impact of discontinuing the diet in those with seizure frequency reduction but not seizure remission is not known. In one study, outcomes at three to six years were evaluated in 54 children who discontinued the diet within one year of initiation [<a href="#rid89">89</a>]. Almost half of these children had &gt;50 percent reduced seizure frequency compared with baseline; 22 percent were seizure-free without surgery. Children who had had some improvement while on the diet were more likely to have a favorable long-term outcome. At our center, approximately 0.5 percent of KDT patients are on the diet for over six years; some have been on the diet for more than 20 years [<a href="#rid133">133</a>].</p><p>Discontinuation of KDT is done in a manner similar to antiseizure medications, with a slow wean over two to three months, reducing the fat to protein plus carbohydrate ratio (ie, lipid to nonlipid) from 4:1 monthly to 3:1, 2:1, and 1:1, followed by reintroduction of regular foods until ketosis is lost [<a href="#rid7">7</a>]. The benefit of this approach is that the ketogenic ratio can be increased should seizures recur or worsen during the weaning period. In one case series, seizure recurrence could be effectively managed in most (58 percent) children with resuming the diet, or adding antiseizure medications [<a href="#rid132">132</a>].</p><p>In some situations, particularly if the diet is either unsuccessful or is associated with worsening seizures, it can be weaned much more rapidly. In a retrospective chart review of 183 children on the diet, speed of diet discontinuation (&lt;1 week, 1 to 6 weeks, or &gt;6 weeks) was not associated with incidence of seizure worsening [<a href="#rid134">134</a>]. We have reduced the ratio weekly for some children, and even abruptly returned to standard diets for children in intensive care unit settings.</p><p class="headingAnchor" id="H2031910925"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113971.html" rel="external">"Society guideline links: Seizures and epilepsy in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/113981.html" rel="external">"Society guideline links: Seizures and epilepsy in children"</a>.)</p><p class="headingAnchor" id="H10153009"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16569.html" rel="external">"Patient education: Epilepsy in children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/139443.html" rel="external">"Patient education: Ketogenic diet (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/139444.html" rel="external">"Patient education: Ketogenic diet and your child (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21469046"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Ketogenic dietary therapy (KDT) is an effective treatment for patients with epilepsy, regardless of age or seizure type. A greater than 50 percent seizure reduction occurs in 38 to 60 percent of patients, with as many as 30 percent achieving a greater than 90 percent seizure reduction. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>KDT is a valid treatment option for patients who have failed at least two antiseizure medications. There are a number of conditions in which KDT may be particularly effective and can be offered earlier in the course of treatment, including Doose syndrome, Dravet syndrome, glucose transporter 1 (GLUT-1) deficiency, infantile spasms, pyruvate dehydrogenase deficiency, and tuberous sclerosis complex; KDT may also be particularly effective for patients with drug-resistant epilepsy who are fed by gastrostomy tube or formula. Patients with intractable focal epilepsy who are candidates for epilepsy surgery are likely to have a better response to epilepsy surgery than to KDT  (<a class="graphic graphic_algorithm graphicRef139450" href="/z/d/graphic/139450.html" rel="external">algorithm 1</a>). (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Before starting KDT, it is important to counsel patients, families, guardians, and caregivers about the implications related to seizure control, antiseizure medication use, and psychosocial issues  (<a class="graphic graphic_table graphicRef120638" href="/z/d/graphic/120638.html" rel="external">table 2</a>). Patients should be screened for potential contraindications and/or factors that may complicate it use. (See <a class="local">'Contraindications'</a> above and <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The major KDTs for the treatment of epilepsy are the classic (long-chain) ketogenic diet, the medium-chain triglyceride diet, the modified Atkins diet, the low glycemic index treatment, and the modified ketogenic diet. The modified Atkins diet and a low glycemic index diet may be useful for adults as well as children. The choice of a particular diet should be based upon individual circumstances. Multivitamins (including minerals such as <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a>), calcium, and vitamin D supplements are given to all patients on KDTs. Some children will require additional supplements  (<a class="graphic graphic_table graphicRef120630" href="/z/d/graphic/120630.html" rel="external">table 3</a>). (See <a class="local">'Composition'</a> above and <a class="local">'Diet selection'</a> above and <a class="local">'Supplementation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>KDT should be supervised by a trained dietitian and neurologist in an epilepsy center with expertise in this form of therapy. The classic ketogenic diet and the medium-chain triglyceride diet are often started in the hospital without a fast period, but alternative approaches are recognized. The modified Atkins diet and the low glycemic index treatment are usually started in the outpatient setting without a fasting period and may be useful for adults as well as children. (See <a class="local">'Composition'</a> above and <a class="local">'Supplementation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients are followed closely with frequent monitoring of clinical status and laboratory tests  (<a class="graphic graphic_table graphicRef120624" href="/z/d/graphic/120624.html" rel="external">table 4</a>). Each visit provides an opportunity to adjust KDT and/or antiseizure medications if needed in order to improve seizure control and reduce adverse effects. Important adverse effects of KDT include gastrointestinal symptoms, dyslipidemia, hypoglycemia, constipation, growth failure, bone disease, and kidney stones. (See <a class="local">'Follow-up and monitoring'</a> above and <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Efficacy of the diet is usually apparent in the first one to three months. If seizure control is achieved, antiseizure medications may be slowly tapered. (See <a class="local">'Antiseizure medication management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>KDT is generally recommended for a minimum of three months and maximum of two years; however, longer periods of effective use have been described. In the absence of severe adverse sequelae, slow taper is advised but the diet can be weaned more quickly if needed. (See <a class="local">'Diet duration and discontinuation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wilder RM. The effect of ketonemia on the course of epilepsy. Mayo Clin Bulletin 1921; 2:307.</a></li><li><a class="nounderline abstract_t">Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 2007; 48:43.</a></li><li><a class="nounderline abstract_t">Bough KJ, Wetherington J, Hassel B, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006; 60:223.</a></li><li><a class="nounderline abstract_t">Danial NN, Hartman AL, Stafstrom CE, Thio LL. How does the ketogenic diet work? Four potential mechanisms. J Child Neurol 2013; 28:1027.</a></li><li><a class="nounderline abstract_t">Olson CA, Vuong HE, Yano JM, et al. The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. Cell 2018; 173:1728.</a></li><li><a class="nounderline abstract_t">Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42:1255.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open 2018; 3:175.</a></li><li><a class="nounderline abstract_t">Shah LM, Turner Z, Bessone SK, et al. How often is antiseizure drug-free ketogenic diet therapy achieved? Epilepsy Behav 2019; 93:29.</a></li><li><a class="nounderline abstract_t">Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008; 7:500.</a></li><li><a class="nounderline abstract_t">Henderson CB, Filloux FM, Alder SC, et al. Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis. J Child Neurol 2006; 21:193.</a></li><li><a class="nounderline abstract_t">Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy. Pediatrics 2000; 105:E46.</a></li><li><a class="nounderline abstract_t">Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev 2020; 6:CD001903.</a></li><li><a class="nounderline abstract_t">Klein P, Janousek J, Barber A, Weissberger R. Ketogenic diet treatment in adults with refractory epilepsy. Epilepsy Behav 2010; 19:575.</a></li><li><a class="nounderline abstract_t">Payne NE, Cross JH, Sander JW, Sisodiya SM. The ketogenic and related diets in adolescents and adults--a review. Epilepsia 2011; 52:1941.</a></li><li><a class="nounderline abstract_t">Schoeler NE, Marston L, Lyons L, et al. Classic ketogenic diet versus further antiseizure medicine in infants with drug-resistant epilepsy (KIWE): a UK, multicentre, open-label, randomised clinical trial. Lancet Neurol 2023; 22:1113.</a></li><li><a class="nounderline abstract_t">Maydell BV, Wyllie E, Akhtar N, et al. Efficacy of the ketogenic diet in focal versus generalized seizures. Pediatr Neurol 2001; 25:208.</a></li><li><a class="nounderline abstract_t">Kang HC, Lee HS, You SJ, et al. Use of a modified Atkins diet in intractable childhood epilepsy. Epilepsia 2007; 48:182.</a></li><li><a class="nounderline abstract_t">Villeneuve N, Pinton F, Bahi-Buisson N, et al. The ketogenic diet improves recently worsened focal epilepsy. Dev Med Child Neurol 2009; 51:276.</a></li><li><a class="nounderline abstract_t">Stainman RS, Turner Z, Rubenstein JE, Kossoff EH. Decreased relative efficacy of the ketogenic diet for children with surgically approachable epilepsy. Seizure 2007; 16:615.</a></li><li><a class="nounderline abstract_t">Jung DE, Kang HC, Kim HD. Long-term outcome of the ketogenic diet for intractable childhood epilepsy with focal malformation of cortical development. Pediatrics 2008; 122:e330.</a></li><li><a class="nounderline abstract_t">Thammongkol S, Vears DF, Bicknell-Royle J, et al. Efficacy of the ketogenic diet: which epilepsies respond? Epilepsia 2012; 53:e55.</a></li><li><a class="nounderline abstract_t">Neal EG, Chaffe H, Schwartz RH, et al. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia 2009; 50:1109.</a></li><li><a class="nounderline abstract_t">Ito S, Oguni H, Ito Y, et al. Modified Atkins diet therapy for a case with glucose transporter type 1 deficiency syndrome. Brain Dev 2008; 30:226.</a></li><li><a class="nounderline abstract_t">Slaughter L, Vartzelis G, Arthur T. New GLUT-1 mutation in a child with treatment-resistant epilepsy. Epilepsy Res 2009; 84:254.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Krauss GL, McGrogan JR, Freeman JM. Efficacy of the Atkins diet as therapy for intractable epilepsy. Neurology 2003; 61:1789.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Rowley H, Sinha SR, Vining EP. A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia 2008; 49:316.</a></li><li><a class="nounderline abstract_t">Carrette E, Vonck K, de Herdt V, et al. A pilot trial with modified Atkins' diet in adult patients with refractory epilepsy. Clin Neurol Neurosurg 2008; 110:797.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Dorward JL, Molinero MR, Holden KR. The modified Atkins diet: a potential treatment for developing countries. Epilepsia 2008; 49:1646.</a></li><li><a class="nounderline abstract_t">Kossoff EH, McGrogan JR, Bluml RM, et al. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia 2006; 47:421.</a></li><li><a class="nounderline abstract_t">Porta N, Vallée L, Boutry E, et al. Comparison of seizure reduction and serum fatty acid levels after receiving the ketogenic and modified Atkins diet. Seizure 2009; 18:359.</a></li><li><a class="nounderline abstract_t">Weber S, Mølgaard C, Karentaudorf, Uldall P. Modified Atkins diet to children and adolescents with medical intractable epilepsy. Seizure 2009; 18:237.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Turner Z, Bluml RM, et al. A randomized, crossover comparison of daily carbohydrate limits using the modified Atkins diet. Epilepsy Behav 2007; 10:432.</a></li><li><a class="nounderline abstract_t">Chapman K, Cardenas JF. Hemimegalencephaly in a patient with a neurocutaneous syndrome. Semin Pediatr Neurol 2008; 15:190.</a></li><li><a class="nounderline abstract_t">Smith M, Politzer N, Macgarvie D, et al. Efficacy and tolerability of the modified Atkins diet in adults with pharmacoresistant epilepsy: a prospective observational study. Epilepsia 2011; 52:775.</a></li><li><a class="nounderline abstract_t">Chen W, Kossoff EH. Long-term follow-up of children treated with the modified Atkins diet. J Child Neurol 2012; 27:754.</a></li><li><a class="nounderline abstract_t">Sharma S, Sankhyan N, Gulati S, Agarwala A. Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial. Epilepsia 2013; 54:481.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Henry BJ, Cervenka MC. Efficacy of dietary therapy for juvenile myoclonic epilepsy. Epilepsy Behav 2013; 26:162.</a></li><li><a class="nounderline abstract_t">Manral M, Dwivedi R, Gulati S, et al. Safety, Efficacy, and Tolerability of Modified Atkins Diet in Persons With Drug-Resistant Epilepsy: A Randomized Controlled Trial. Neurology 2023; 100:e1376.</a></li><li><a class="nounderline abstract_t">Kossoff EH. The Modified Atkins Diet for Epilepsy: Two Decades of an "Alternative" Ketogenic Diet Therapy. Pediatr Neurol 2023; 147:82.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Bosarge JL, Miranda MJ, et al. Will seizure control improve by switching from the modified Atkins diet to the traditional ketogenic diet? Epilepsia 2010; 51:2496.</a></li><li><a class="nounderline abstract_t">Muzykewicz DA, Lyczkowski DA, Memon N, et al. Efficacy, safety, and tolerability of the low glycemic index treatment in pediatric epilepsy. Epilepsia 2009; 50:1118.</a></li><li><a class="nounderline abstract_t">Grocott OR, Herrington KS, Pfeifer HH, et al. Low glycemic index treatment for seizure control in Angelman syndrome: A case series from the Center for Dietary Therapy of Epilepsy at the Massachusetts General Hospital. Epilepsy Behav 2017; 68:45.</a></li><li><a class="nounderline abstract_t">Green SF, Nguyen P, Kaalund-Hansen K, et al. Effectiveness, retention, and safety of modified ketogenic diet in adults with epilepsy at a tertiary-care centre in the UK. J Neurol 2020; 267:1171.</a></li><li><a class="nounderline abstract_t">Poorshiri B, Barzegar M, Tahmasebi S, et al. The efficacy comparison of classic ketogenic diet and modified Atkins diet in children with refractory epilepsy: a clinical trial. Acta Neurol Belg 2021; 121:483.</a></li><li><a class="nounderline abstract_t">Kilaru S, Bergqvist AG. Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia. Epilepsia 2007; 48:1703.</a></li><li><a class="nounderline abstract_t">Caraballo RH, Cersósimo RO, Sakr D, et al. Ketogenic diet in patients with myoclonic-astatic epilepsy. Epileptic Disord 2006; 8:151.</a></li><li><a class="nounderline abstract_t">Oguni H, Tanaka T, Hayashi K, et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002; 33:122.</a></li><li><a class="nounderline abstract_t">Wiemer-Kruel A, Haberlandt E, Hartmann H, et al. Modified Atkins diet is an effective treatment for children with Doose syndrome. Epilepsia 2017; 58:657.</a></li><li><a class="nounderline abstract_t">Nickels K, Kossoff EH, Eschbach K, Joshi C. Epilepsy with myoclonic-atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort. Epilepsia 2021; 62:120.</a></li><li><a class="nounderline abstract_t">Mullen SA, Marini C, Suls A, et al. Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy. Arch Neurol 2011; 68:1152.</a></li><li><a class="nounderline abstract_t">Klepper J, Leiendecker B. GLUT1 deficiency syndrome--2007 update. Dev Med Child Neurol 2007; 49:707.</a></li><li><a class="nounderline abstract_t">Leen WG, Klepper J, Verbeek MM, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 2010; 133:655.</a></li><li><a class="nounderline abstract_t">Klepper J, Scheffer H, Leiendecker B, et al. Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics 2005; 36:302.</a></li><li><a class="nounderline abstract_t">Kass HR, Winesett SP, Bessone SK, et al. Use of dietary therapies amongst patients with GLUT1 deficiency syndrome. Seizure 2016; 35:83.</a></li><li><a class="nounderline abstract_t">Fujii T, Ito Y, Takahashi S, et al. Outcome of ketogenic diets in GLUT1 deficiency syndrome in Japan: A nationwide survey. Brain Dev 2016; 38:628.</a></li><li><a class="nounderline abstract_t">Hao J, Kelly DI, Su J, Pascual JM. Clinical Aspects of Glucose Transporter Type 1 Deficiency: Information From a Global Registry. JAMA Neurol 2017; 74:727.</a></li><li><a class="nounderline abstract_t">Ramm-Pettersen A, Nakken KO, Skogseid IM, et al. Good outcome in patients with early dietary treatment of GLUT-1 deficiency syndrome: results from a retrospective Norwegian study. Dev Med Child Neurol 2013; 55:440.</a></li><li><a class="nounderline abstract_t">Ramm-Pettersen A, Stabell KE, Nakken KO, Selmer KK. Does ketogenic diet improve cognitive function in patients with GLUT1-DS? A 6- to 17-month follow-up study. Epilepsy Behav 2014; 39:111.</a></li><li><a class="nounderline abstract_t">Pascual JM, Liu P, Mao D, et al. Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement. JAMA Neurol 2014; 71:1255.</a></li><li><a class="nounderline abstract_t">Wexler ID, Hemalatha SG, McConnell J, et al. Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations. Neurology 1997; 49:1655.</a></li><li><a class="nounderline abstract_t">Weber TA, Antognetti MR, Stacpoole PW. Caveats when considering ketogenic diets for the treatment of pyruvate dehydrogenase complex deficiency. J Pediatr 2001; 138:390.</a></li><li><a class="nounderline abstract_t">Sofou K, Dahlin M, Hallböök T, et al. Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes. J Inherit Metab Dis 2017; 40:237.</a></li><li><a class="nounderline abstract_t">Hosain SA, La Vega-Talbott M, Solomon GE. Ketogenic diet in pediatric epilepsy patients with gastrostomy feeding. Pediatr Neurol 2005; 32:81.</a></li><li><a class="nounderline abstract_t">Kossoff EH, McGrogan JR, Freeman JM. Benefits of an all-liquid ketogenic diet. Epilepsia 2004; 45:1163.</a></li><li><a class="nounderline abstract_t">Wusthoff CJ, Kranick SM, Morley JF, Christina Bergqvist AG. The ketogenic diet in treatment of two adults with prolonged nonconvulsive status epilepticus. Epilepsia 2010; 51:1083.</a></li><li><a class="nounderline abstract_t">Bodenant M, Moreau C, Sejourné C, et al. [Interest of the ketogenic diet in a refractory status epilepticus in adults]. Rev Neurol (Paris) 2008; 164:194.</a></li><li><a class="nounderline abstract_t">Nam SH, Lee BL, Lee CG, et al. The role of ketogenic diet in the treatment of refractory status epilepticus. Epilepsia 2011; 52:e181.</a></li><li><a class="nounderline abstract_t">Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia 2010; 51:2033.</a></li><li><a class="nounderline abstract_t">Kumada T, Miyajima T, Kimura N, et al. Modified Atkins diet for the treatment of nonconvulsive status epilepticus in children. J Child Neurol 2010; 25:485.</a></li><li><a class="nounderline abstract_t">Cervenka MC, Hocker S, Koenig M, et al. Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus. Neurology 2017; 88:938.</a></li><li><a class="nounderline abstract_t">Bergqvist AG, Chee CM, Lutchka LM, Brooks-Kayal AR. Treatment of acquired epileptic aphasia with the ketogenic diet. J Child Neurol 1999; 14:696.</a></li><li><a class="nounderline abstract_t">Kang HC, Lee YM, Kim HD, et al. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007; 48:82.</a></li><li><a class="nounderline abstract_t">Vaisleib II, Buchhalter JR, Zupanc ML. Ketogenic diet: outpatient initiation, without fluid, or caloric restrictions. Pediatr Neurol 2004; 31:198.</a></li><li><a class="nounderline abstract_t">Bansal S, Cramp L, Blalock D, et al. The ketogenic diet: initiation at goal calories versus gradual caloric advancement. Pediatr Neurol 2014; 50:26.</a></li><li><a class="nounderline abstract_t">Seo JH, Lee YM, Lee JS, et al. Efficacy and tolerability of the ketogenic diet according to lipid:nonlipid ratios--comparison of 3:1 with 4:1 diet. Epilepsia 2007; 48:801.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Dorward JL. The modified Atkins diet. Epilepsia 2008; 49 Suppl 8:37.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Dorward JL, Turner Z, Pyzik PL. Prospective study of the modified atkins diet in combination with a ketogenic liquid supplement during the initial month. J Child Neurol 2011; 26:147.</a></li><li><a class="nounderline abstract_t">Cervenka MC, Terao NN, Bosarge JL, et al. E-mail management of the modified Atkins Diet for adults with epilepsy is feasible and effective. Epilepsia 2012; 53:728.</a></li><li><a class="nounderline abstract_t">Pfeifer HH, Thiele EA. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. Neurology 2005; 65:1810.</a></li><li><a class="nounderline abstract_t">Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 1971; 21:1097.</a></li><li><a class="nounderline abstract_t">Feldstein TJ. Carbohydrate and alcohol content of 200 oral liquid medications for use in patients receiving ketogenic diets. Pediatrics 1996; 97:506.</a></li><li><a class="nounderline abstract_t">Siegel BI, Johnson M, Dawson TE, et al. Reducing Prescribing Errors in Hospitalized Children on the Ketogenic Diet. Pediatr Neurol 2021; 115:42.</a></li><li><a class="nounderline abstract_t">Haney CA, Charpentier A, Turner Z, et al. A Proof-of-Principle, Case-Control Study to Compensate for Potential Carbohydrates in Liquid Antiseizure Drugs in Children on the Ketogenic Diet. J Child Neurol 2019; 34:367.</a></li><li><a class="nounderline abstract_t">Bergqvist AG, Schall JI, Gallagher PR, et al. Fasting versus gradual initiation of the ketogenic diet: a prospective, randomized clinical trial of efficacy. Epilepsia 2005; 46:1810.</a></li><li><a class="nounderline abstract_t">Lin A, Turner Z, Doerrer SC, et al. Complications During Ketogenic Diet Initiation: Prevalence, Treatment, and Influence on Seizure Outcomes. Pediatr Neurol 2017; 68:35.</a></li><li><a class="nounderline abstract_t">Freeman JM, Vining EP. Seizures decrease rapidly after fasting: preliminary studies of the ketogenic diet. Arch Pediatr Adolesc Med 1999; 153:946.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Laux LC, Blackford R, et al. When do seizures usually improve with the ketogenic diet? Epilepsia 2008; 49:329.</a></li><li><a class="nounderline abstract_t">McNally MA, Pyzik PL, Rubenstein JE, et al. Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet. Pediatrics 2009; 124:e300.</a></li><li><a class="nounderline abstract_t">Marsh EB, Freeman JM, Kossoff EH, et al. The outcome of children with intractable seizures: a 3- to 6-year follow-up of 67 children who remained on the ketogenic diet less than one year. Epilepsia 2006; 47:425.</a></li><li><a class="nounderline abstract_t">Kang HC, Chung DE, Kim DW, Kim HD. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia 2004; 45:1116.</a></li><li><a class="nounderline abstract_t">Caraballo R, Vaccarezza M, Cersósimo R, et al. Long-term follow-up of the ketogenic diet for refractory epilepsy: multicenter Argentinean experience in 216 pediatric patients. Seizure 2011; 20:640.</a></li><li><a class="nounderline abstract_t">Kwiterovich PO Jr, Vining EP, Pyzik P, et al. Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA 2003; 290:912.</a></li><li><a class="nounderline abstract_t">Nizamuddin J, Turner Z, Rubenstein JE, et al. Management and risk factors for dyslipidemia with the ketogenic diet. J Child Neurol 2008; 23:758.</a></li><li><a class="nounderline abstract_t">Zamani GR, Mohammadi M, Ashrafi MR, et al. The effects of classic ketogenic diet on serum lipid profile in children with refractory seizures. Acta Neurol Belg 2016; 116:529.</a></li><li><a class="nounderline abstract_t">Liu YM, Lowe H, Zak MM, et al. Can children with hyperlipidemia receive ketogenic diet for medication-resistant epilepsy? J Child Neurol 2013; 28:479.</a></li><li><a class="nounderline abstract_t">Güzel O, Yılmaz U, Uysal U, Arslan N. The effect of olive oil-based ketogenic diet on serum lipid levels in epileptic children. Neurol Sci 2016; 37:465.</a></li><li><a class="nounderline abstract_t">McDonald TJW, Diaz-Arias L, Vizthum D, et al. Six-month effects of modified Atkins diet implementation on indices of cardiovascular disease risk in adults with epilepsy. Nutr Neurosci 2022; 25:1548.</a></li><li><a class="nounderline abstract_t">Takeoka M, Riviello JJ Jr, Pfeifer H, Thiele EA. Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. Epilepsia 2002; 43:1072.</a></li><li><a class="nounderline abstract_t">Hawkes CP, Levine MA. Ketotic hypercalcemia: a case series and description of a novel entity. J Clin Endocrinol Metab 2014; 99:1531.</a></li><li><a class="nounderline abstract_t">Yılmaz Ü, Nalbantoğlu Ö, Güzin Y, et al. The effect of ketogenic diet on thyroid functions in children with drug-resistant epilepsy. Neurol Sci 2021; 42:5261.</a></li><li><a class="nounderline abstract_t">Vining EP, Pyzik P, McGrogan J, et al. Growth of children on the ketogenic diet. Dev Med Child Neurol 2002; 44:796.</a></li><li><a class="nounderline abstract_t">Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. Dev Med Child Neurol 2006; 48:978.</a></li><li><a class="nounderline abstract_t">Williams S, Basualdo-Hammond C, Curtis R, Schuller R. Growth retardation in children with epilepsy on the ketogenic diet: a retrospective chart review. J Am Diet Assoc 2002; 102:405.</a></li><li><a class="nounderline abstract_t">Groleau V, Schall JI, Stallings VA, Bergqvist CA. Long-term impact of the ketogenic diet on growth and resting energy expenditure in children with intractable epilepsy. Dev Med Child Neurol 2014; 56:898.</a></li><li><a class="nounderline abstract_t">Spulber G, Spulber S, Hagenäs L, et al. Growth dependence on insulin-like growth factor-1 during the ketogenic diet. Epilepsia 2009; 50:297.</a></li><li><a class="nounderline abstract_t">Neal EG, Chaffe HM, Edwards N, et al. Growth of children on classical and medium-chain triglyceride ketogenic diets. Pediatrics 2008; 122:e334.</a></li><li><a class="nounderline abstract_t">Berry-Kravis E, Booth G, Sanchez AC, Woodbury-Kolb J. Carnitine levels and the ketogenic diet. Epilepsia 2001; 42:1445.</a></li><li><a class="nounderline abstract_t">Bergqvist AG, Schall JI, Stallings VA. Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia 2007; 48:66.</a></li><li><a class="nounderline abstract_t">Bergqvist AG, Schall JI, Stallings VA, Zemel BS. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr 2008; 88:1678.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Pyzik PL, Furth SL, et al. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 2002; 43:1168.</a></li><li><a class="nounderline abstract_t">Arslan N, Kose E, Guzel O. The Effect of Ketogenic Diet on Serum Selenium Levels in Patients with Intractable Epilepsy. Biol Trace Elem Res 2017; 178:1.</a></li><li><a class="nounderline abstract_t">Bank IM, Shemie SD, Rosenblatt B, et al. Sudden cardiac death in association with the ketogenic diet. Pediatr Neurol 2008; 39:429.</a></li><li><a class="nounderline abstract_t">Bergqvist AG, Chee CM, Lutchka L, et al. Selenium deficiency associated with cardiomyopathy: a complication of the ketogenic diet. Epilepsia 2003; 44:618.</a></li><li><a class="nounderline abstract_t">Sirikonda NS, Patten WD, Phillips JR, Mullett CJ. Ketogenic diet: rapid onset of selenium deficiency-induced cardiac decompensation. Pediatr Cardiol 2012; 33:834.</a></li><li><a class="nounderline abstract_t">Munro K, Keller AE, Lowe H, et al. Neutropenia in Children Treated With Ketogenic Diet Therapy. J Child Neurol 2021; 36:525.</a></li><li><a class="nounderline abstract_t">Best TH, Franz DN, Gilbert DL, et al. Cardiac complications in pediatric patients on the ketogenic diet. Neurology 2000; 54:2328.</a></li><li><a class="nounderline abstract_t">Lyczkowski DA, Pfeifer HH, Ghosh S, Thiele EA. Safety and tolerability of the ketogenic diet in pediatric epilepsy: effects of valproate combination therapy. Epilepsia 2005; 46:1533.</a></li><li><a class="nounderline abstract_t">Stewart WA, Gordon K, Camfield P. Acute pancreatitis causing death in a child on the ketogenic diet. J Child Neurol 2001; 16:682.</a></li><li><a class="nounderline abstract_t">Coppola G, Natale F, Torino A, et al. The impact of the ketogenic diet on arterial morphology and endothelial function in children and young adults with epilepsy: a case-control study. Seizure 2014; 23:260.</a></li><li><a class="nounderline abstract_t">Kapetanakis M, Liuba P, Odermarsky M, et al. Effects of ketogenic diet on vascular function. Eur J Paediatr Neurol 2014; 18:489.</a></li><li><a class="nounderline abstract_t">Patel A, Pyzik PL, Turner Z, et al. Long-term outcomes of children treated with the ketogenic diet in the past. Epilepsia 2010; 51:1277.</a></li><li><a class="nounderline abstract_t">Dahlin MG, Beck OM, Amark PE. Plasma levels of antiepileptic drugs in children on the ketogenic diet. Pediatr Neurol 2006; 35:6.</a></li><li><a class="nounderline abstract_t">Kverneland M, Taubøll E, Molteberg E, et al. Pharmacokinetic interaction between modified Atkins diet and antiepileptic drugs in adults with drug-resistant epilepsy. Epilepsia 2019; 60:2235.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Pyzik PL, McGrogan JR, Rubenstein JE. The impact of early versus late anticonvulsant reduction after ketogenic diet initiation. Epilepsy Behav 2004; 5:499.</a></li><li><a class="nounderline abstract_t">Morrison PF, Pyzik PL, Hamdy R, et al. The influence of concurrent anticonvulsants on the efficacy of the ketogenic diet. Epilepsia 2009; 50:1999.</a></li><li><a class="nounderline abstract_t">van der Louw EJ, Desadien R, Vehmeijer FO, et al. Concomitant lamotrigine use is associated with decreased efficacy of the ketogenic diet in childhood refractory epilepsy. Seizure 2015; 32:75.</a></li><li><a class="nounderline abstract_t">Selter JH, Turner Z, Doerrer SC, Kossoff EH. Dietary and medication adjustments to improve seizure control in patients treated with the ketogenic diet. J Child Neurol 2015; 30:53.</a></li><li><a class="nounderline abstract_t">van der Louw E, van den Hurk D, Neal E, et al. Ketogenic diet guidelines for infants with refractory epilepsy. Eur J Paediatr Neurol 2016; 20:798.</a></li><li><a class="nounderline abstract_t">Coppola G, Epifanio G, Auricchio G, et al. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain Dev 2006; 28:358.</a></li><li><a class="nounderline abstract_t">Stevens CE, Turner Z, Kossoff EH. Hepatic Dysfunction as a Complication of Combined Valproate and Ketogenic Diet. Pediatr Neurol 2016; 54:82.</a></li><li><a class="nounderline abstract_t">Ballaban-Gil K, Callahan C, O'Dell C, et al. Complications of the ketogenic diet. Epilepsia 1998; 39:744.</a></li><li><a class="nounderline abstract_t">Martinez CC, Pyzik PL, Kossoff EH. Discontinuing the ketogenic diet in seizure-free children: recurrence and risk factors. Epilepsia 2007; 48:187.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Turner Z, Bergey GK. Home-guided use of the ketogenic diet in a patient for more than 20 years. Pediatr Neurol 2007; 36:424.</a></li><li><a class="nounderline abstract_t">Worden LT, Turner Z, Pyzik PL, et al. Is there an ideal way to discontinue the ketogenic diet? Epilepsy Res 2011; 95:232.</a></li></ol></div><div id="topicVersionRevision">Topic 14438 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The effect of ketonemia on the course of epilepsy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241207" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Anticonvulsant mechanisms of the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16807920" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23670253" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : How does the ketogenic diet work? Four potential mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29804833" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737159" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effectiveness of first antiepileptic drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29881797" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30831398" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : How often is antiseizure drug-free ketogenic diet therapy achieved?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456557" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901419" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10742367" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32588435" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ketogenic diets for drug-resistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937568" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ketogenic diet treatment in adults with refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22004525" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The ketogenic and related diets in adolescents and adults--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37977712" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Classic ketogenic diet versus further antiseizure medicine in infants with drug-resistant epilepsy (KIWE): a UK, multicentre, open-label, randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587874" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy of the ketogenic diet in focal versus generalized seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241226" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of a modified Atkins diet in intractable childhood epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19191829" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The ketogenic diet improves recently worsened focal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17544706" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Decreased relative efficacy of the ketogenic diet for children with surgically approachable epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676519" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term outcome of the ketogenic diet for intractable childhood epilepsy with focal malformation of cortical development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22310062" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy of the ketogenic diet: which epilepsies respond?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054400" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17869467" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Modified Atkins diet therapy for a case with glucose transporter type 1 deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237265" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : New GLUT-1 mutation in a child with treatment-resistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694049" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy of the Atkins diet as therapy for intractable epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919301" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A prospective study of the modified Atkins diet for intractable epilepsy in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18572306" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A pilot trial with modified Atkins' diet in adult patients with refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18782218" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The modified Atkins diet: a potential treatment for developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16499770" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196525" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of seizure reduction and serum fatty acid levels after receiving the ketogenic and modified Atkins diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054697" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Modified Atkins diet to children and adolescents with medical intractable epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17324628" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomized, crossover comparison of daily carbohydrate limits using the modified Atkins diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19073327" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hemimegalencephaly in a patient with a neurocutaneous syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21269295" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and tolerability of the modified Atkins diet in adults with pharmacoresistant epilepsy: a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22532541" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Long-term follow-up of children treated with the modified Atkins diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23294191" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23266114" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy of dietary therapy for juvenile myoclonic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36599697" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Safety, Efficacy, and Tolerability of Modified Atkins Diet in Persons With Drug-Resistant Epilepsy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37591065" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Modified Atkins Diet for Epilepsy: Two Decades of an "Alternative" Ketogenic Diet Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21204815" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Will seizure control improve by switching from the modified Atkins diet to the traditional ketogenic diet?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220406" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy, safety, and tolerability of the low glycemic index treatment in pediatric epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28109989" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Low glycemic index treatment for seizure control in Angelman syndrome: A case series from the Center for Dietary Therapy of Epilepsy at the Massachusetts General Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31925498" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effectiveness, retention, and safety of modified ketogenic diet in adults with epilepsy at a tertiary-care centre in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31677042" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The efficacy comparison of classic ketogenic diet and modified Atkins diet in children with refractory epilepsy: a clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17651420" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16793577" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ketogenic diet in patients with myoclonic-astatic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200741" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28229464" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Modified Atkins diet is an effective treatment for children with Doose syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33190223" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Epilepsy with myoclonic-atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555602" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17718830" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : GLUT1 deficiency syndrome--2007 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20129935" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16217704" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26803281" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Use of dietary therapies amongst patients with GLUT1 deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26923720" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Outcome of ketogenic diets in GLUT1 deficiency syndrome in Japan: A nationwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28437535" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical Aspects of Glucose Transporter Type 1 Deficiency: Information From a Global Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23448551" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Good outcome in patients with early dietary treatment of GLUT-1 deficiency syndrome: results from a retrospective Norwegian study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25240122" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Does ketogenic diet improve cognitive function in patients with GLUT1-DS? A 6- to 17-month follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25110966" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409363" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241048" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Caveats when considering ketogenic diets for the treatment of pyruvate dehydrogenase complex deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28101805" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15664765" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ketogenic diet in pediatric epilepsy patients with gastrostomy feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15329084" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Benefits of an all-liquid ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845731" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The ketogenic diet in treatment of two adults with prolonged nonconvulsive status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18358881" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : [Interest of the ketogenic diet in a refractory status epilepticus in adults].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22003821" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The role of ketogenic diet in the treatment of refractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813015" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19779207" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Modified Atkins diet for the treatment of nonconvulsive status epilepticus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28179470" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10593544" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of acquired epileptic aphasia with the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241212" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15351019" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ketogenic diet: outpatient initiation, without fluid, or caloric restrictions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24200038" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The ketogenic diet: initiation at goal calories versus gradual caloric advancement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17386059" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy and tolerability of the ketogenic diet according to lipid:nonlipid ratios--comparison of 3:1 with 4:1 diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19049584" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The modified Atkins diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20833798" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prospective study of the modified atkins diet in combination with a ketogenic liquid supplement during the initial month.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22332768" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : E-mail management of the modified Atkins Diet for adults with epilepsy is feasible and effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344529" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5166216" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Medium-chain triglycerides as a therapy for intractable childhood epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8632936" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Carbohydrate and alcohol content of 200 oral liquid medications for use in patients receiving ketogenic diets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33333459" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Reducing Prescribing Errors in Hospitalized Children on the Ketogenic Diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30782060" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A Proof-of-Principle, Case-Control Study to Compensate for Potential Carbohydrates in Liquid Antiseizure Drugs in Children on the Ketogenic Diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16302862" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fasting versus gradual initiation of the ketogenic diet: a prospective, randomized clinical trial of efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28188074" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Complications During Ketogenic Diet Initiation: Prevalence, Treatment, and Influence on Seizure Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10482210" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Seizures decrease rapidly after fasting: preliminary studies of the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18028405" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : When do seizures usually improve with the ketogenic diet?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19596731" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16499771" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The outcome of children with intractable seizures: a 3- to 6-year follow-up of 67 children who remained on the ketogenic diet less than one year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15329077" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Early- and late-onset complications of the ketogenic diet for intractable epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21763159" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Long-term follow-up of the ketogenic diet for refractory epilepsy: multicenter Argentinean experience in 216 pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12928468" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18658075" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Management and risk factors for dyslipidemia with the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26791878" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The effects of classic ketogenic diet on serum lipid profile in children with refractory seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23427065" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Can children with hyperlipidemia receive ketogenic diet for medication-resistant epilepsy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26700799" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The effect of olive oil-based ketogenic diet on serum lipid levels in epileptic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33487129" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Six-month effects of modified Atkins diet implementation on indices of cardiovascular disease risk in adults with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12199733" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24606099" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Ketotic hypercalcemia: a case series and description of a novel entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33846882" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The effect of ketogenic diet on thyroid functions in children with drug-resistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12455855" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Growth of children on the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17109786" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Long-term use of the ketogenic diet in the treatment of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11902374" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Growth retardation in children with epilepsy on the ketogenic diet: a retrospective chart review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24749520" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Long-term impact of the ketogenic diet on growth and resting energy expenditure in children with intractable epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18727678" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Growth dependence on insulin-like growth factor-1 during the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676520" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Growth of children on classical and medium-chain triglyceride ketogenic diets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11879348" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Carnitine levels and the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241209" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064531" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12366731" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27873289" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The Effect of Ketogenic Diet on Serum Selenium Levels in Patients with Intractable Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19027591" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Sudden cardiac death in association with the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681013" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Selenium deficiency associated with cardiomyopathy: a complication of the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22367552" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Ketogenic diet: rapid onset of selenium deficiency-induced cardiac decompensation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33393840" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Neutropenia in Children Treated With Ketogenic Diet Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10881264" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Cardiac complications in pediatric patients on the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16146450" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Safety and tolerability of the ketogenic diet in pediatric epilepsy: effects of valproate combination therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11575609" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Acute pancreatitis causing death in a child on the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24380692" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The impact of the ketogenic diet on arterial morphology and endothelial function in children and young adults with epilepsy: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24703903" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Effects of ketogenic diet on vascular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132287" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Long-term outcomes of children treated with the ketogenic diet in the past.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16814078" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Plasma levels of antiepileptic drugs in children on the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31602644" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Pharmacokinetic interaction between modified Atkins diet and antiepileptic drugs in adults with drug-resistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15256185" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : The impact of early versus late anticonvulsant reduction after ketogenic diet initiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389152" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The influence of concurrent anticonvulsants on the efficacy of the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552568" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Concomitant lamotrigine use is associated with decreased efficacy of the ketogenic diet in childhood refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24859788" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Dietary and medication adjustments to improve seizure control in patients treated with the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470655" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Ketogenic diet guidelines for infants with refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376041" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26706483" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Hepatic Dysfunction as a Complication of Combined Valproate and Ketogenic Diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9670903" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Complications of the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241227" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Discontinuing the ketogenic diet in seizure-free children: recurrence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17560509" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Home-guided use of the ketogenic diet in a patient for more than 20 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536412" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Is there an ideal way to discontinue the ketogenic diet?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
